Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

Investigational New Drugs
Jing LiSharyn D Baker

Abstract

Gefitinib exhibits wide inter-subject pharmacokinetic variability which may contribute to differences in treatment outcome. Unbound drug concentrations are believed to be more relevant to pharmacological and toxicological responses than total drug. Thus it is desirable to determine gefitinib binding in plasma and factors affecting this process. An equilibrium dialysis method using 96-well microdialysis plates was optimized and validated for determining the fraction unbound (fu) gefitinib in human plasma. Gefitinib binding in plasma from four different species and isolated protein solutions as well as drug partitioning in human blood cells were investigated. Unbound gefitinib plasma concentrations were measured in 21 cancer patients receiving daily oral gefitinib 250 mg or 500 mg. It was found that gefitinib was extensively bound in human rat mouse and dog plasma with mean fu values of 3.4%, 3.8%, 5.1% and 6.0% respectively. In isolated protein solutions approximately 90% and 78% of gefitinib was bound to human serum albumin (HSA) (40 mg/dL) and alpha1-acid glycoprotein (AAG) (1.4 mg/dL) with binding constants of 1.85 x 10(4) M(-1) and 1.13 x 10(5) M(-1) respectively. In whole blood 2.8% of gefitinib existed as the free drug whi...Continue Reading

References

Sep 28, 1998·Cancer Chemotherapy and Pharmacology·E A SausvilleS Kobayashi
Aug 24, 1999·Pharmacology & Therapeutics·J R Woodburn
Oct 19, 2000·Journal of the National Cancer Institute·C Gambacorti-PasseriniM D'Incalci
Dec 29, 2000·Drugs·J Baselga, S D Averbuch
Apr 5, 2001·Journal of Pharmaceutical Sciences·K R KuchimanchiA K Mitra
May 11, 2001·Cancer Chemotherapy and Pharmacology·L van ZuylenA Sparreboom
Oct 2, 2001·The Netherlands Journal of Medicine·A SparreboomJ Verweij
May 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masahiro FukuokaJosé Baselga
Oct 10, 2003·Clinical Pharmacology and Therapeutics·Walter J LoosAlex Sparreboom
Aug 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·William PaoHarold Varmus
Dec 30, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sharyn D BakerAlex Sparreboom
Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William Pao, Vincent A Miller
Mar 31, 2005·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Ming ZhaoSharyn D Baker
May 12, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pasi A JänneBruce E Johnson

❮ Previous
Next ❯

Citations

Aug 26, 2009·International Journal of Clinical Oncology·Susumu AraiNoriyuki Masuda
Dec 7, 2006·Journal of the National Cancer Institute·Jing LiSharyn D Baker
Oct 24, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Yong LiuMark J Ratain
Feb 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard A GrahamPatricia M Lorusso
Feb 22, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jianmei WuJing Li
Aug 11, 2011·Bioanalysis·Florin Marcel Musteata
Jun 15, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Nicolas WidmerAlain Astier
Sep 19, 2008·Expert Opinion on Drug Metabolism & Toxicology·Bo GaoHoward Gurney
Jun 27, 2013·Journal of Pharmaceutical Sciences·Tonika Bohnert, Liang-Shang Gan
Mar 13, 2015·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Seung-Hoon BeomDae Seog Heo
Aug 1, 2012·Clinical Lung Cancer·Jing ZhaoMengzhao Wang
Sep 14, 2010·Cancer Treatment Reviews·Heinz-Josef KlümpenHoward Gurney
Jun 15, 2010·Pharmacology & Therapeutics·Michele VisentinGiuseppe Toffoli
Sep 8, 2009·Cancer Treatment Reviews·Nielka P van ErpHenk-Jan Guchelaar
Aug 22, 2009·British Journal of Clinical Pharmacology·Stephanie ChhunStephane Mouly
Dec 19, 2008·Clinical Pharmacology and Therapeutics·S D Baker, S Hu
Jul 17, 2015·Cancer Cell International·Khalid O AlfaroukCyril Rauch
Feb 24, 2015·Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine·Pardeep KumarAnil K Mishra
Feb 26, 2016·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Brian S BogdanowiczMegan E Hartranft
Aug 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bo GaoHoward Gurney
Feb 16, 2018·Journal of Biomolecular Structure & Dynamics·Hamid TanzadehpanahMassoud Saidijam
Apr 24, 2019·Archiv der Pharmazie·Mrunal J SharmaY C Mayur
May 11, 2011·Clinical Pharmacokinetics·Matthias SchefflerUwe Fuhr
Aug 29, 2014·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Rosie A JohnstonMichael Murray
Feb 15, 2017·European Journal of Drug Metabolism and Pharmacokinetics·Prashant B NigadeKumar V S Nemmani
Jun 25, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Brian D FurmanskiSharyn D Baker
Jul 30, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Brian MadajewskiCameron Brennan
Jun 21, 2020·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Christina FinkSheila-Annie Peters
Sep 3, 2021·European Journal of Pharmacology·Ling-Jun JieYan Wang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.